Chronic myelogenous leukemia | |
---|---|
Other names | Chronic myeloid leukemia, chronic granulocytic leukemia (CGL) |
![]() | |
The Philadelphia chromosome as seen by fluorescent in situ hybridization (FISH). | |
Specialty | Hematology and oncology |
Symptoms | Early: None, tiredness, left upper
abdominal pain
[1] Later: Headache, bone pain, fever, enlarged lymph nodes [1] |
Complications | Bleeding, priapism [1] |
Usual onset | 56 years old [1] |
Risk factors | Atomic bomb exposure [1] |
Diagnostic method | Complete blood cell count (CBC), cytogenetic testing [1] |
Differential diagnosis | Other causes of leukocytosis, chronic neutrophilic leukemia, polycythemia vera [1] |
Prognosis | Five-year survival rate 70% [2] |
Frequency | 298,000 (2015) [3] |
Deaths | 32,200 (2015) [4] |
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a type of cancer which involves white blood cells, primarily granulocytes. [1] Both the blood and bone marrow are affected. [1] At the time of diagnosis about half of people have no symptoms. [1] Early symptoms may include tiredness and left upper abdominal pain due to an enlarged spleen. [1] Later symptoms may include headache, bone pain, fever, and enlarged lymph nodes. [1] Complications may include bleeding and priapism. [1]
Few risk factors have been defined, though it is more common among those who survived the atomic bomb. [1] More than 90% of those affected have a Philadelphia chromosome which forms due to a chromosomal translocation. [1] It is a type of myeloproliferative neoplasm. [1] The diagnosis is suspected based on a complete blood cell count (CBC) and confirmed by cytogenetic testing. [1] The disease can be divided into three phases, chronic, accelerated, and blastic. [5]
Treatment is with a group of medications known as tyrosine-kinase inhibitors (TKIs). [1] These includes imatinib, bosutinib, dasatinib, and nilotinib. [1] Other options may include bone marrow transplant and omacetaxine. [1] With the availability of TKIs the five-year survival rate has increased from 33% to more than 70%. [1] [2]
About 0.9 per 100,000 people are newly affected per year. [1] The typical age of diagnosis is around 56 years old. [1] In Western countries, it accounts for 20% of adult leukemias. [6] It is rare in children. [5] The underlying cause was determined in 1960 By Nowell and Hungerford. [7]
<youtube>fT_NTuZSbkQ</youtube>
{{
cite journal}}
: Cite journal requires |journal=
(
help)